An observational study in Pregnancy, sponsored by Amryt Pharma. Terminated at 1 site in Germany. Open to female participants. Per ClinicalTrials.gov, last updated 2022-12-16.
Sponsored by Amryt Pharma · Observational
To evaluate the outcomes of pregnancy in women treated with lomitapide.
To evaluate the outcomes of pregnancy in women treated with lomitapide at any time within 30 days prior to first day of Last Menstrual Period (LMP) or during pregnancy. The outcomes of primary interest are major congenital anomalies.
Amryt Pharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Pregnant Females
Exclusion Criteria:
As prescribed by Physician.
Also known as: Juxtapid, Lojuxta
Pregnancy
To evaluate the outcomes of pregnancy in women treated with lomitapide at any time within 30 days prior to first day of Last Menstrual Period (LMP) or during pregnancy. The outcomes of primary interest are major congenital anomalies.
Time frame: 2 Years
This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amryt Pharma